SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Large B-cell lymphoma expressing the ALK kinase and lacking the t(2;5) translocation
This is a neoplasm of ALK-positive monomorphic large immunoblast-like B cells, sometimes with plasmablastic differentiation. This lymphoma is very rare (<1% of DLBCL) with less than 40 cases reported so far.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see code 9684/3.) This is a very rare neoplasm. The tumor involves mainly lymph nodes or presents as a mediastinal mass. Involvement of extranodal sites have also been reported (nasopharynx, tongue, stomach, bone and soft tissues). Most patients present with Stage III/IV. Because these tumors are negative for CD20 antigen, they are insensitive to rituximab.